Cascadian Therapeutics Announces Poster Presentations on Tucatinib at the European Society of Medical Oncology (ESMO) 2016 Co...
September 28 2016 - 8:00AM
Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage
biopharmaceutical company, today announced two upcoming poster
presentations on tucatinib (ONT-380), the Company’s lead product
candidate for the treatment of HER2+ breast cancer, at the European
Society of Medical Oncology (ESMO) 2016 Congress being held October
7 -11, 2016 in Copenhagen, Denmark.
Details of Poster Presentations:
Title: Cutaneous responses in Her-2+ metastatic
breast cancer (MBC) on phase 1b study of ONT-380, an oral
HER2-specific inhibitor in combination with capecitabine (C) and/or
trastuzumab (T) in third line or later treatmentPoster
Number: 278Date: Monday, October 10,
2016Time: 1:00pm – 2:00pm (CEST)
Title: A phase 2 randomized, double-blinded,
controlled study of ONT-380 vs. placebo in combination with
capecitabine (C) and trastuzumab (T) in patients with pretreated
HER2+ unresectable locally advanced or metastatic breast carcinoma
(MBC) Poster Number: 312 (trial in
progress)Date: Monday, October 10,
2016Time: 1:00pm – 2:00pm (CEST)
About Cascadian Therapeutics Cascadian
Therapeutics is a clinical-stage biopharmaceutical company
dedicated to developing innovative product candidates for the
treatment of cancer. Our lead product candidate, tucatinib, also
known as ONT-380, is an orally active and selective small molecule
HER2 inhibitor, which has been studied in approximately 200
patients to date. Preliminary results from two ongoing Phase 1b
studies of tucatinib in combination showed promising systemic
activity, a favorable safety profile and encouraging activity
against brain metastases. Cascadian Therapeutics is also conducting
a randomized, double-blind, placebo-controlled Phase 2 study
called HER2CLIMB. The study is evaluating tucatinib versus
placebo in combination with capecitabine and trastuzumab in late
stage HER2+ breast cancer patients, with and without brain
metastases, who have previously been treated with a taxane,
trastuzumab, pertuzumab and T-DM1. This study is expected to
enroll 180 patients across approximately 100 clinical sites in the
U.S., Canada, and Western Europe. The Company is also developing a
cell cycle inhibitor, Chk1, and plans to move the program forward
through IND-enabling studies in 2017. For more information,
visit www.cascadianrx.com.
Investor Contact:
Julie Rathbun
Rathbun Communications
206-769-9219
ir@cascadianrx.com
Naomi Eichenbaum
The Trout Group
646-378-2968
neichenbaum@troutgroup.com
Media Contact:
Susie Myers
BMC Communications
646-513-3116
smyers@bmccommunications.com
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Sep 2023 to Sep 2024